A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)

Trial Profile

A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Ganetespib (Primary) ; Doxorubicin
  • Indications Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Oct 2016 Status changed from recruiting to discontinued.
    • 09 Sep 2015 Interim results (n=6) presented at the 16th World Conference on Lung Cancer.
    • 14 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top